araag2/HINT huggingface dataset:
Clinical trial NCT01211626 (phase 1, status: completed)
Conditions: hcv infection
ICD codes: K94.02, K94.12, K94.22, K94.32, N99.511, A02.9, A31.0
Drugs: ana773, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Part A Inclusion:

          -  Male or female, ages 18 to 65 years

          -  No clinically significant abnormalities

          -  No serious or severe chronic conditions

          -  Non-smokers

        Part A Exclusion:

          -  Female subjects who are pregnant or breast-feeding

          -  History of significant medical condition that could interfere with study medication or
             associated study assessments

          -  History of or current drug or alcohol abuse

        Part B Inclusion Criteria:

          -  Male or female, ages 18 to 65 years

          -  Diagnosed with chronic liver disease consistent with chronic hepatitis C infection for
             at least 6 months

          -  Screening HCV RNA ≥ 375,000 copies/mL or ≥ 75,000 IU/mL

          -  Naïve to or have relapsed from prior IFN-alpha based therapy

        Part B Exclusion Criteria:

          -  Female subjects who are pregnant or breast-feeding

          -  Received anti-viral therapy or immunomodulatory therapy within 90 days prior to
             administration of the first dose of study medication

          -  Use of an investigational drug or participation in an investigational study with a
             licensed drug within 30 days

          -  History of significant medical condition that could interfere with study medication or
             associated study assessments

          -  History of or current drug or alcohol abuse
Clinical trial NCT01188304 (phase 1, status: completed)
Conditions: healthy volunteer
ICD codes: Y99.2
Drugs: aleglitazar, aspirin, placebo
SMILES: CO[C@@H](CC1=CC=C(OCCC2=C(C)OC(=N2)C2=CC=CC=C2)C2=C1SC=C2)C(O)=O, CC(=O)OC1=CC=CC=C1C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy volunteers, aged 40 to 65 years inclusive

          -  Body Mass Index (BMI) between 18 and 35 kg/m2 inclusive

          -  Females of child-bearing potential must be willing to use two acceptable methods of
             contraception during the study and at least 3 months before start of the study

          -  Non-smoker or currently smoking less than 5 cigarettes (or equivalent amount of other
             tobacco products) per day and is willing and able to stop smoking during the period in
             study center

          -  Volunteer drinks no more than 3 cups of coffee, tea or soft drinks per day and is
             willing and able to stop drinking coffee, tea and soft drinks during the period in
             study center

        Exclusion Criteria:

          -  Any clinically relevant abnormal laboratory test results at screening

          -  Volunteer has taken any prescribed, herbal or over-the-counter medication within 2
             weeks prior to first dosing

          -  A history of any clinical significant gastro-intestinal, cardiovascular,
             musculoskeletal, endocrine, hematological, psychiatric, renal, hepatic,
             bronchopulmonary or neurological conditions or lipid disorders

          -  A positive test for human immunodeficiency virus (HIV-1 or HIV-2), hepatitis B or
             hepatitis C

          -  History of intolerance to non-steroidal anti-inflammatory drugs (NSAIDs) or aspirin,
             history of gastric or duodenal ulceration, personal or family history of abnormal
             clotting or bleeding
Clinical trial NCT00424645 (phase 1/phase 2, status: terminated)
Conditions: hematologic malignancy, solid tumor
ICD codes: E70.338, E70.339, P09.3, O28.0, P61.8, P61.9, T45.8X1A
Drugs: voraxaze (glucarpidase), placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    sponsor terminated due to low accrual.
  
Eligibility criteria:

        Inclusion Criteria:

          1. Patients with solid tumors and hematologic malignancies, receiving high dose
             methotrexate (MTX) (> / = 1 g/m^2 up to 14 g/m^2), who have delayed MTX clearance.
             Delayed MTX clearance is defined as: a) Serum MTX level at 72 +/- 2 hrs from
             initiation of infusion > / = 0.1 µmol/L for MTX doses 1-3.5 g/m^2 OR b) Serum MTX
             level at 72 +/- 2 hrs from initiation of infusion > / = 0.3 µmol/L for MTX doses > 3.5
             g/m^2

          2. Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          3. IRB-approved signed informed consent

        Exclusion Criteria:

          1. Any medical or psychiatric illness that is deemed by the investigator to be likely to
             interfere with patient's ability to sign informed consent, cooperate and participate
             in the study

          2. Patients receiving medications which may interfere with MTX excretion or enhance MTX
             toxicity (e.g. Penicillins, Cephalosporins, Tetracyclines, Non-Steroidal
             Anti-inflammatory Agents, Salicylates, Thiazide Diuretics, Bactrim, and Probenecid)

          3. Patients with uncontrolled cardiac disease such as uncontrolled angina, cardiac
             arrhythmia, or Congestive Heart Failure (CHF) (New York Heart Association (NYHA) 4)

          4. Patients with known hypersensitivity to any of the components of the study drug
Clinical trial NCT01278056 (phase 1/phase 2, status: completed)
Conditions: non-alcoholic steatohepatitis, increased iron storage / disturbed distribution
ICD codes: K75.81
Drugs: exjade
SMILES: CC(C)N1CCN(CC1)C1=CC=C(OC[C@H]2CO[C@@](CN3C=NC=N3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
Eligibility criteria:

        Inclusion Criteria (shortened):

          -  Patients with elevated liver enzymes

          -  Elevated serum ferritin (females > 300 ng/ml, males > 450 ng/ml)

          -  Liver Histology consistent with a diagnosis of NASH

        Exclusion Criteria (shortened):

          -  Alcohol intake > 140 g/week

          -  Established liver cirrhosis Child Pugh B or C

          -  Copresence of other causes of chronic liver disease

          -  Anemia < 10 g/dl

          -  Any elevation of liver enzymes > 5 ULN (ALAT, ASAT, g-GT), > 2.5 ULN (other), > 1.5
             (Bilirubin)

          -  Serum creatinine > 1.4 mg/dl or Ccr < 60 ml/min

          -  Hemochromatosis

          -  Known allergy or contraindication to the administration of Deferasirox

          -  Sexually active pre-menopausal female patients who are unable to use a highly
             effective method of birth control. An exception is made for those who have undergone
             clinically documented total hysterectomy and/or oophorectomy, tubal ligation.

          -  Patients with impaired coagulation

          -  History of blood transfusion during the 6 months prior to study entry

          -  Oral iron supplementation within the last 4 weeks of study entry

          -  Treatment with phlebotomy within 2 weeks of screening visit

          -  Desferal treatment within 1 month of the screening visit

          -  Patients currently or previously treated with deferiprone or Deferasirox

          -  Presence of a surgical or medical condition that might significantly alter the
             absorption, distribution, metabolism or excretion of any study drug

          -  Positive HIV serology

          -  Patients with active inflammatory diseases that may interfere with the accurate
             measurement of serum ferritin

          -  Patients with a diagnosis of a clinically relevant cataract or a previous history of
             clinically relevant ocular toxicity related to iron chelation

          -  Pregnant or breast feeding patients

          -  Patients treated with systemic investigational drug within 4 weeks prior or with
             topical investigational drug within 7 days prior to the screening visit

          -  Medications with proven or suspected influence on NASH such as glitazones, statins, or
             metformin are no exclusion criteria for study entry (insulin is not regarded to
             interfere with NASH).
Clinical trial NCT00547053 (phase 1, status: completed)
Conditions: cystic fibrosis
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: amiloride solution for inhalation
SMILES: NC(N)=NC(=O)C1=C(N)N=C(N)C(Cl)=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of Cystic Fibrosis

          -  Two positive cultures for Burkholderia dolosa lung infection

        Exclusion Criteria:

          -  Positive pregnancy test or currently breast feeding (if applicable)

          -  Known sensitivity to Amiloride
Clinical trial NCT00316407 (phase 1/phase 2, status: completed)
Conditions: ovarian epithelial cancer stage iii, stage iv ovarian cancer, stage iv breast cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: lapatinib (gw572016), carboplatin, paclitaxel
SMILES: CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Relapsed (Stage III or IV) ovarian, primary peritoneal, fallopian tube carcinoma
             patients.

          -  Stage IV metastatic breast cancer patients who have failed no more than four previous
             chemotherapies for Stage IV disease.

          -  Ability to swallow and retain oral medications.

          -  Measurable disease

        Exclusion Criteria:

          -  Treatment with previous weekly carboplatin and paclitaxel.

          -  No prior treatment with erbB targeting therapies such as erlotinib, gefitinib and
             cetuximab.

          -  No concomitant requirement for medication classification as CYP3A4 inducers or
             inhibitors.
Clinical trial NCT01474083 (phase 1/phase 2, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: gk1-399 (formerly ttp399), gk1-399 (formerly ttp399), gk1-399 (formerly ttp399), placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Be male or female, aged 18 through 75 years at screening.

          -  Have a diagnosis of Type 2 Diabetes Mellitus (T2DM)

          -  On a stable dose of background medication for the treatment of diabetes

          -  Body Mass Index (BMI) between 20-40 kg/m2 (inclusive)

        Exclusion Criteria:

          -  Subjects with type 1 diabetes, heart attack or stroke in the past 6 months,
             uncontrolled blood pressure, significant kidney disease
Clinical trial NCT00467116 (phase 1, status: completed)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: gemcitabine hydrochloride
SMILES: NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed adenocarcinoma of the pancreas (head, body, or tail) or
             periampullary region, meeting both of the following criteria:

               -  Unresectable disease

               -  Locally advanced disease

          -  Measurable or evaluable disease by CT scan or MRI

          -  No evidence of metastatic disease outside of the planned irradiation field

          -  ECOG performance status 0-2

          -  WBC ≥ 3,000/mm³

          -  ANC ≥ 1,500/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Hemoglobin ≥ 8.5 g/dL

          -  AST and ALT ≤ 5 times upper limit of normal

          -  Bilirubin ≤ 2.0 mg/dL

          -  Creatinine ≤ 2.0 mg/dL

          -  No clinical indication of compromised function of nonirradiated kidney

          -  No secondary malignancies within the past 5 years except for resected nonmelanoma skin
             cancer or carcinoma in situ of the cervix

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        Exclusion Criteria:

          -  No acute hepatitis

          -  No known HIV infection

          -  No other active or uncontrolled infection

          -  No significant history of uncontrolled cardiac disease, including any of the
             following:

               -  Hypertension

               -  Unstable angina

               -  Myocardial infarction within the past 6 months

               -  Congestive heart failure

               -  Cardiomyopathy with decreased ejection fraction

          -  No prior severe infusion reaction to a monoclonal antibody

        PRIOR CONCURRENT THERAPY:

          -  No prior radiotherapy to planned field of treatment

          -  No prior therapy that specifically and directly targets EGFR pathway

          -  At least 14 days since prior surgery or biopsy

          -  At least 28 days since prior bypass procedures

          -  More than 5 years since prior and no other concurrent chemotherapy

          -  No other concurrent investigational agent
Clinical trial NCT00326586 (phase 1, status: completed)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: ar antagonist (bms-641988)
SMILES: CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CN=CC=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Advanced castration-resistant prostate carcinoma with progressive disease

          -  At least 4 weeks must have elapsed from major surgery

          -  Patient must be available for follow-up

          -  Adequate liver and kidney function

          -  Adequate blood values

        Exclusion Criteria:

          -  Uncontrolled or significant heart disease

          -  History of seizures

          -  History of head injury, loss of consciousness, or stroke

          -  Patients undergoing alcohol withdrawal

          -  Any concurrent cancer

          -  A serious uncontrolled medical disorder or active infection

          -  Inability to swallow tablets
Clinical trial NCT00122876 (phase 1/phase 2, status: completed)
Conditions: carcinoma, hepatocellular, liver neoplasms
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8, D13.4, Z85.05, C22.8, C78.7, C22.9, D37.6
Drugs: talaporfin sodium
SMILES: CCC1=C(C)\C2=C\C3=C(C=C)C(C)=C(N3)\C=C3/N=C([C@@H](CCC(O)=O)[C@@H]3C)/C(/CC(=O)N[C@@H](CC(O)=O)C(O)=O)=C3\N\C(=C/C1=N2)C(C)=C3C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  A diagnosis of primary Hepatocellular Carcinoma (HCC), established by any one of the
             following criteria in a clinical setting suggestive of HCC: (i) Two different imaging
             techniques that suggests HCC; (ii) Combination of one imaging technique that suggests
             HCC and serum alpha-fetoprotein (AFP) level >400 ng/mL; (iii) Histological evidence of
             HCC;

          -  Subjects with at least 1 but no more than 3 lesions in the liver may be considered for
             enrollment in the study;

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2;

          -  Life expectancy of at least 16 weeks;

          -  Prior treatment failure with locally ablative techniques is allowed. Subjects who were
             not candidates for surgery, systemic chemotherapy, chemoembolization (TACE),
             intratumoral ethanol injection (PEI), radiofrequency ablation (RFA), cryoablation or
             other locally ablative technology may be eligible, but at least 4 weeks must have
             elapsed since the completion of any prior therapy and the subject must have recovered
             from acute side effects;

          -  Understanding and ability to sign written informed consent;

          -  18 years of age or more;

          -  Adequate hematologic, liver and renal functions as evidenced by the following: *WBC >
             2,400/mm; *Platelet Count > 75,000/µl; *Hemoglobin > 9.4 gm/dL; *PT and PTT < 1.5
             Control; *AST, ALT < 5 x ULN; *Bilirubin < 1.5 X ULN; *Alk Phos < 3X ULN; *Creatinine
             < 2.5 mg/dL (SI: 221 mmol/L)

        Exclusion Criteria:

          -  Subjects who are candidates for surgery with curative intent;

          -  Subjects with lesions larger than 8 cm in diameter and more than 40% of parenchymal
             disease involvement;

          -  Known sensitivity to porphyrin type drugs;

          -  Known history of porphyria;

          -  Known presence of extrahepatic metastases;

          -  Anticipated need for systemic chemotherapy during the first 8 weeks of the study;

          -  Child-Pugh C cirrhosis;

          -  Diffuse HCC;

          -  Concurrent participation in another clinical trial involving experimental treatment;

          -  Any concurrent disease or condition that in the opinion of the investigator impairs
             the subject's ability to complete the trial. Psychological, familial, sociological,
             geographical or medical conditions which in the Principal Investigator's opinion could
             compromise compliance with the objectives and procedures of this protocol or obscure
             interpretation of the trial's data.
Clinical trial NCT00635557 (phase 1/phase 2, status: unknown status)
Conditions: glioblastoma multiforme
ICD codes: L51.0, L51.8, L51.9
Drugs: mpc-6827 + carboplatin
SMILES: COC1=CC=C(C=C1)N(C)C1=NC(C)=NC2=C1C=CC=C2
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically proven WHO Grade IV glioblastoma multiforme at time of diagnosis or
             relapse

          -  Prior treatment with radiotherapy and temozolomide

          -  Evidence of measurable recurrent or residual primary tumor by contrast-enhanced MRI

          -  Be a minimum of 4 weeks since prior surgical resection, major surgical procedure,
             radiation therapy or cytotoxic chemotherapy (6 weeks since prior BCNU or CCNU)

          -  Have a Performance Scale of Karnofsky > 60%, ECOG < 2 or WHO < 2

          -  If steroids are needed, be on a stable or decreasing dose of steroids for at least 1
             week

        Exclusion Criteria:

          -  Hypersensitivity to Cremophor EL

          -  Have evidence of current/active intratumor hemorrhage by MRI

          -  Have greater than second relapse

          -  Have had prior treatment with platinum-based chemotherapy

          -  Have cardiovascular disease

          -  Have cerebrovascular disease

          -  Have uncontrolled hypertension

          -  Have a cardiac ejection fraction < 50%

          -  Have Troponin-I elevated above the normal range
Clinical trial NCT01372761 (phase 1, status: completed)
Conditions: obesity
ICD codes: E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211
Drugs: zgn-433, normal saline
SMILES: CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C1=CC=C(OCCN(C)C)C=C1, O
Eligibility criteria:

        Inclusion Criteria:

          -  Obese but otherwise healthy females

          -  Non-childbearing potential (surgically sterile, post-menopausal, or receiving
             implanted or injectable contraceptive for at least 3 months)

          -  BMI ≥ 30 and ≤ 50 kg/m2

          -  Stable body weight during the past month

        Exclusion Criteria:

          -  Use of weight loss agents in the past month

          -  History of eating disorder

          -  History of gastric bypass surgery

          -  Current smokers
Clinical trial NCT00593008 (phase 1, status: terminated)
Conditions: pancreatic adenocarcinoma
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: temsirolimus, gemcitabine
SMILES: CN1N=NC2=C(N=CN2C1=O)C(N)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Previously untreated metastatic pancreatic adenocarcinoma, histologically proven.

          -  Measurable disease by RECIST criteria

          -  ECOG Performance Status 0 or 1

          -  Male or female, 18 years of age or older

          -  Life expectancy of >/= 12 weeks

          -  AST and ALT </= 2.5 x ULN

          -  Total bilirubin </= 1.5 x ULN

          -  Serum albumin >/= 2.5g/dL

          -  Absolute neutrophil count >/= 1500/mm3; platelets >/= 100,000/mm3; hemoglobin >/= 9.0
             g/dL

          -  Serum creatinine </= 1.5 x ULN

          -  Subjects with diabetes must have adequate glycemic control, with fasting serum glucose
             </= 1.5 x ULN

          -  Female patients of childbearing age and male patients with partners of childbearing
             age must agree to use adequate birth control measures during the course of the study
             and for at least one month following withdrawal from the study

        Exclusion Criteria:

          -  Previously treatment with gemcitabine or chemoradiation

          -  Diagnosis of a second malignancy within the last 3 years, except for adequately
             treated basal cell carcinoma or squamous cell skin cancer

          -  Ongoing cardiac dysrhythmias of NCI CTCAE grade >/= 2, atrial fibrillation, QTc
             prolongation to > 450 msec for males and >470 msec for females

          -  Known immunodeficiency disorders or active infections requiring treatment

          -  Pregnancy or breastfeeding

          -  Known brain metastases, spinal cord compression, carcinomatous meningitis, or
             leptomeningeal disease

          -  Prior radiation therapy or major surgery within 4 weeks of study entry

          -  Prior radiation therapy to > 25% of the bone marrow

          -  Subjects receiving other experimental or alternative therapies during the course of
             the trial will be excluded

          -  History of prior hypersensitivity to polysorbate
Clinical trial NCT00509899 (phase 1/phase 2, status: completed)
Conditions: myelofibrosis, polycythemia vera, thrombocytosis
ICD codes: D75.81, C94.41, C94.42, C94.40, D45
Drugs: ruxolitinib
SMILES: N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed with PMF or Post-PV/ET MF

          -  Patients with myelofibrosis requiring therapy

          -  Adequate bone marrow reserve

        Exclusion Criteria:

          -  Received anti-cancer medications or investigational therapy in the past 14 days
Clinical trial NCT01536704 (phase 1, status: completed)
Conditions: smoking cessation
ICD codes: Y36.881S, Y36.891S, Y36.880S, Y36.881A, Y36.881D, Y36.890S, Y36.891A
Drugs: nicotine (2 mg), nicotine (4 mg)
SMILES: CN1CCC[C@H]1C1=CN=CC=C1, CN1CCC[C@H]1C1=CN=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Participants must be healthy smokers who usually smoked their first cigarette within
             30 minutes of waking.

          -  Body Mass Index within the range 19-27 kilograms/meters^2

        Exclusion Criteria:

          -  Participants who used chewing tobacco or tobacco products other than cigarettes within
             21 days of screening visit